Skip to main content Help with accessibility Skip to main navigation


This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.

Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.

Definitions and Criteria for Categorisation of Medicines

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.


Date Added: 15 - Oct - 2021

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of EMPAGLIFLOZIN tablets (Jardiance®) for treating chronic heart failure with reduced ejection fraction.

Body System:
Date Added: 28 - Oct - 2021

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of EVOLOCUMAB injection (Repatha SureClick®) for reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease.


Body System: